1-804-709-0144
About ImmunArray

Board of Directors

Board of Directors

Donna J. Edmonds, Chairman and Chief Executive Officer

Donna has over 30 years of healthcare experience both as a provider and as an industry executive. She has been a leader in introducing and commercializing products and technologies that have revolutionized patient care. She was Hospital Administrator (Director of Nursing) and General Manager of a specialty physician group. Donna spent eight years with Baxter International where she held Senior Executive positions in Business Development, Sales and Marketing. She also spent many years as a public and private start-up company executive. Donna has served in senior management roles for 10 diagnostic companies including as Senior Vice President, Sales & Market Development for Ischemia Technologies, which was sold to Inverness Medical the precedent company of Alere Diagnostics, recently acquired by Abbott. She remained with Inverness following the acquisition serving as Senior Vice President, Market and Business Development for the Cardiovascular Strategic Business Unit.

Robert C. Sledd

Bob is an advisor to New Richmond Ventures and managing partner of Pinnacle Ventures LLC and Sledd Properties, a family commercial real estate company. Previously, he was with Performance Food Group, a company which he co-founded in 1987 and where he served in the roles of President, CEO and Chairman until the company’s acquisition by and merger with Vistar and Roma Food in 2008. Bob also serves on the corporate boards of Owens & Minor, SCP Pool Corporation, Universal Corporation, and Bon Secours Health System, Richmond. He was also senior economic advisor to Virginia Governor’s office from 2010-2013. Long active in community affairs, Bob currently serves on the board of VCU School of Business Foundation and Homeward’s Board of Advocates. Past board service includes the Management Roundtable and nonprofits such as Venture Richmond and Better Housing Coalition.

Timothy Schroeder

Tim, CEO and Founder of Clinical Trial and Consulting (CTI), has over 35 years of clinical, academic, and industry experience in global drug and device development programs. CTI, founded in 1999, is a multi-national research firm with associates in North America, Europe, Latin America and Asia-Pacific. The firm has supported more than 100 drug and device approvals, and currently works on behalf of approximately 120 global pharmaceutical and biotechnology companies. Prior to founding CTI, Tim held numerous faculty positions with the University Of Cincinnati College Of Medicine. He was also the founding Executive Vice President of Clinical Development at SangStat Medical Corporation, which went public in 1995. Tim is currently a board member for over a dozen corporate and non-profit organizations, including Xavier University, which he attended. Tim was named as an EY Entrepreneur of the Year in 2015.

Tim Black

Tim is Chief Financial Officer at Fusion Company and brings over 20 years of finance and accounting experience to the board. He has served as a chief financial officer, investment banker and business owner. Previously, he was a Principal with MDA Advisors where he provided financial and strategic advice to middle market and growth companies. Prior to that, he was a founding member of Cary Street Partners, an investment banking and wealth management firm where he advised numerous companies on mergers and acquisitions, capital raising strategies, and other strategic initiatives. Prior to Cary Street, he was with Wachovia Securities in the Technology Investment Banking Group. He was also senior auditor with Arthur Andersen. He holds a BS in Accounting from the University of Richmond and an MBA from the Darden School at the University of Virginia.

Dick Aderman

Dick joined HYCOR Biomedical in 2010 as President and CEO. Dick has an extensive background in diagnostics and healthcare. From 1980 through 1996 he held various positions in sales, marketing and general management with American Hospital Corporation, Baxter Healthcare and Dade International and from 1997 through mid-2005, Dick was a member of senior management at Boehringer Mannheim later acquired by Roche Diagnostics. There he led in the explosive growth of Roche through his leadership in Corporate Accounts, amassing an impressive record of successful contract negations resulting in double digit growth. During this time period, Roche Diagnostics became the number one diagnostics company in the U.S. and achieved the top ranking in customer satisfaction. From mid-2005 until joining HYCOR, Dick was involved in leadership positions with early and mid-stage start-ups in disease management software, medical devices and marketing consulting.